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A B S T R A C T
Purpose
To investigate the prognostic role of genomic gain for MET and epidermal growth factor receptor
(EGFR) genes in surgically resected non–small-cell lung cancer (NSCLC).
Patients and Methods
This retrospective study included 447 NSCLC patients with available tumor tissue from primary
lung tumor and survival data. EGFR and MET status was evaluated by fluorescent in situ
hybridization (FISH) in tissue microarray sections.
Results
EGFR FISH results were obtained in 376 cases. EGFR gene amplification and high polysomy
(EGFR FISH) were observed in 10.4% and 32.4% of cases, respectively. EGFR FISH-positive
patients had a nonsignificant shorter survival than EGFR FISH-negative patients (P .4). Activating
EGFR mutations were detected in 9.7% of 144 stage I-II disease with no impact on survival. MET
FISH analysis was performed in 435 cases. High MET gene copy number (mean  5 copies/cell)
was observed in 48 cases (MET, 11.1%), including 18 cases with true gene amplification (4.1%).
MET status was associated with advanced stage (P  .01), with grade 3 (P  .016) and with
EGFR FISH result (P  .0001). No patient with activating EGFR mutation resulted MET. In the
whole population, MET-positive patients had shorter survival than MET-negative patients
(P  .005). Multivariable model confirmed that MET-negative patients had a significant reduction
in the risk of death than MET-positive patients (hazard ratio, 0.66; P  .04).
Conclusion
MET increased gene copy number is an independent negative prognostic factor in surgically
resected NSCLC. EGFR gene gain does not impact survival after resection.
J Clin Oncol 27:1667-1674. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Since its identification, the epidermal growth factor
receptor (EGFR) has emerged as one of the most
relevant targets for cancer treatment.1 During the
past few years, anti-EGFR strategies offered new
hopes to patients with metastatic non–small-cell
lung cancer (NSCLC). Cetuximab (C225, Erbitux;
ImClone System Inc, New York, NY), a monoclonal
antibody against the extracellular domain of EGFR,
modestly but significantly prolonged survival of
chemotherapy-naive NSCLC patients when used
in combination with cisplatin and vinorelbine.2
Erlotinib (OSI 774; Tarceva; Genentech, South San
Francisco, CA), an orally available EGFR tyrosine
kinase inhibitor (TKI), significantly prolonged sur-
vival when used as single agent in pretreated
NSCLC.3 Studies in NSCLC with EGFR-TKIs or
cetuximab showed that these agents are partic-
ularly effective in individuals with certain biologic
characteristics.4-6 Increased EGFR gene copy num-
ber detected by fluorescent in situ hybridization
(FISH) emerged as the strongest predictor for sur-
vival in retrospective analyses of large phase III trials
comparing EGFR-TKI versus placebo.7-9 More re-
cently, a retrospective analysis of NSCLC patients
treated with chemotherapy plus cetuximab showed
prolonged progression-free survival for individuals
with increased EGFR gene copy number (EGFR
FISH positive) when compared to EGFR FISH neg-
ative.10 Although these data indicated a predictive
value of EGFR gene gain, other studies raised the
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possibility that this event may be associated with a better natural
history.11-12 The impact of EGFR protein expression and gene copy
number on survival of surgically resected NSCLC patients is not a
resolved issue. Distinct studies conducted at the protein level did not
reach similar conclusions regarding duration of survival and level of
EGFR expression.13-22 Studies at the gene level using FISH have not
shown significant survival difference between patients with high or
low EGFR copy numbers; however, the scoring criteria were different
than described in studies of patients treated with EGFR-TKIs.22-24
MET is the receptor for hepatocyte growth factor and frequently
overexpresses in NSCLC.25-27 Previous studies described MET gene
amplification in up to 10% of gastric cancers,28 in 4% of esophageal
cancer,29 and in endometrial cancer.30 In addition to proliferative and
antiapoptotic activities that are common to many growth factors,
MET activation demonstrated to stimulate cell-cell detachment, mi-
gration, and invasiveness.31 Preclinical findings suggested that lung
cancer cell lines harboringMET gene amplification are dependent on
MET for growth and survival.32 Recent data showed thatMET ampli-
fication is a rare event in NSCLC, occurring in up to 7% of cases.33-35
The rarity of MET amplification in NSCLC, particularly at the high
level observed in TKI-resistant cell-line models,34,36 suggested that this
event plays a limited role in primary resistance to EGFR-TKI. In
contrast, MET gene amplification is one of the most relevant mecha-
nisms involved in EGFR-TKI acquired resistance. Engelman et al36
reported that NSCLC overcomes inhibition of EGFR-TKIs by ampli-
fying the MET oncogene to activate HER3, a member of the EGFR
family, and the PI3K-AKT cell survival pathway. In another study,
Bean et al33 showed MET amplification in 21% of patients with ac-
quired resistance to gefitinib or erlotinib and only in 3% of untreated
patients, confirming that MET could be a relevant therapeutic target
for some individuals with acquired resistance to EGFR-TKIs.
The conflicting data on the prognostic value of EGFR together
with the relevance of MET as a potential target against NSCLC and the
absence of data onMET gene copy number effect on survival led us to
conduct a study aiming to evaluate the prognostic effect of EGFR/
MET in NSCLC patients.
PATIENTS AND METHODS
Patient Selection
This retrospective study was conducted in a cohort of 447 NSCLC pa-
tients that received a radical resection of a primary NSCLC at Istituto Clinico
Humanitas IRCCS, Rozzano, Italy, during 2000 to 2004. The only criteria used
for patient selection included availability of tumor tissue from primary lung
cancer and survival data. Paraffin-embedded tumor specimens were used to
construct a tissue microarray with 600-m diameter cores. Each patient was
represented by three tissue cores. An adhesive-coated tape system (Instrumed-
ics, Hackensack, NJ) was used for sectioning the tumor array blocks at 4m.
The study was approved by the local ethics committee and was conducted in
accordance with ethical principles stated in the most recent version of the
Declaration of Helsinki or the applicable guidelines on good clinical practice,
whichever represented the greater protection of the individuals.
FISH Analyses
Unstained 4-m sections from each of the three tissue microarray were
submitted to dual-color FISH assays using the EGFR/CEP7 probe set from
Abbott Molecular (Abbott Park, IL) and aMET/CEP7 probe cocktail prepared
with the in house developedMETDNA (RP 11-95I20 BAC clone) labeled with
SpectrumRed and the SpectrumGreen CEP7 (Abbott Molecular). The FISH
assays were performed according to protocol previously described,5 including
pretreatment with 2 sodium chloride-sodium citrate buffer at 75°C and
digestion with proteinase K for 7 to 15 minutes each, codenaturation at 85°C
for 15 minutes, hybridization for approximately 36 hours, and rapid posthy-
bridization washes with 2 sodium chloride-sodium citrate buffer/0.4 nonyl-
phenoxyl-polyethoxylethanol. Signals were enumerated in at least 50 tumor
nuclei per core, using epifluorescence microscope with single interference
filters sets for green (FITC), red (Texas red) and blue (DAPI) as well as dual
(red/green) and triple (blue, red, green) band pass filters. For each core, the
mean and standard deviation of copy number per cell of each tested DNA
sequence, the percentage of cells with 2, 3, and 4 copies of the EGFR and
MET genes, and the ratioEGFR/CEP7 andMET/CEP7 were calculated. When
heterogeneous results were detected among the three tested cores, the core
with the highest mean copy number was used to represent the patient in the
statistic analyses. For documentation, images were captured using a CCD
camera and merged using dedicated software (CytoVision; Genetix USA,
Boston, MA).
Mutation Analysis
Genomic DNA was extracted from tumors and normal lung tissues
according to standard procedures. Genetic analysis of exons 19 and 21of the
EGFR gene was performed by PCR–single-strand conformation polymor-
phism and direct sequencing as previously described,37 with the following
modifications. Sample were amplified in triplicate and run side by side in order
to exclude artifactual sequence changes which are common events in
formalin-fixed, paraffin-embedded samples.38-39 Samples harboring muta-
tions were reamplified in duplicates, using the same experimental conditions,
purified and subjected to bidirectional dye-terminator sequencing with the
same primers employed for amplification. Sequencing fragments were de-
tected by capillary electrophoresis using the ABI Prism 3100 DNA analyzer
(Applied Biosystems, Foster City, CA). Sequence chromatograms were ana-
lyzed by Mutation Surveyor 2.61 (SoftGenetics, State College, PA), followed by
manual review.
Statistical Analyses
The primary end point was to assess whether EGFR andMET gene copy
number affected survival of surgically resected NSCLC. Overall survival (OS),
calculated from the time of diagnosis to patient death or last contact, and the
95% CIs were evaluated by survival analysis using Kaplan-Meier method.40
Associations with clinical characteristics were compared by Fisher’s exact test
or 2 test. OS for the groups with negative and positive biomarkers were
compared using the log-rank test. Statistical significance was set at lower than
.05 for each analysis. Multivariable analysis was performed using Cox propor-
tional hazards regression analysis with a step-down procedure method. The
criterion for variable removal was the likelihood ratio statistic based on the
maximum partial likelihood estimates (defaultP value of .10 for removal from
the model). Observations were independent and the proportional hazard
assumption was respected. All statistical analyses were performed using SPSS
version 11.5.1 (SPSS Italia srl, Bologna, Italy).
RESULTS
Patient Characteristics
A total of 447 surgically resected NSCLC patients were included
in this analysis. As presented in Table 1, the majority of patients were
male (83.4%), former (51.9%) or current (35.1%) smokers, with
moderately or poorly differentiated tumors (grade 2 and 3). The
median age was 66 years. All patients received radical surgery, with
evidence of pathologic stage III in 34.7% and stage IV in 6% of cases.
Patients with metastatic disease received surgery following or at the
same time of single brain or lung lesion removal.
Because adjuvant chemotherapy become a standard approach
only after 2004, no postoperative therapy was delivered to patients in
stage I-II, and only a minority of patients with stage III disease (18
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cases) received adjuvant platinum-based chemotherapy. Patients with
stage III disease and pathological evidence of N2 disease (n  101)
received postoperative mediastinal radiotherapy.
With a median follow-up of 40 months, in the whole population
OS was 43.9 months. As expected, median survival was longer in stage
I-II than in stage III-IV (not reached v 22.3 months; P .0001). No
significant difference in survival was observed according to sex, smok-
ing history, histology, or grading.
EGFR FISH Results
EGFR copy number was evaluated by FISH in 376 cases, and a
total of 161 cases (42.8%) were considered as FISH positive according
to criteria adopted for selection of patients candidate for EGFR-TKI
therapy and described elsewhere.5 Positive patients included 39 cases
with true gene amplification (10.4%) and 122 cases with high poly-
somy (32.4%). As illustrated in Figure 1A, median survival was longer
in the EGFR FISH-negative (48.3 months) than in patients with high
polysomy (40.7 months) or EGFR gene amplification (30.7 months).
Patients with trueEGFR gene amplification had shorter survival when
compared with the other two groups combined (30.7 v 44.6 months),
even if the difference was not statistically significant (P .85). More-
over, as illustrated in Figure 1B, the difference in survival between
EGFR FISH-positive and FISH-negative groups was not statistically
significant (40.7 v 48.3 months; P .4).
We further analyzed the survival outcome of EGFR FISH-
positive and FISH-negative patients according to clinical characteris-
tics, and no significant difference was observed, as presented in Table 2.
MET FISH Results
METwas evaluated in 435 cases, and the median meanMETgene
copy number was 3.27 (mean range, 1.5 to 21.9 copies per cell).
Patients were classified in six groups according to the ascendingMET
gene copy number, as illustrated in Figure 2A. Because the survival
outcome of patients with a mean MET gene copy number per cell
higher than 5 and higher than 6 was similar and worse than the other
four groups with a mean copy number lower than 5, we considered as
MET FISH-positive all cases with mean 5 copies per cell and nega-
tive all cases with mean fewer than 5 copies per cell. Using this cutoff,
a total of 48 patients (11.1%) resulted MET FISH positive, including
18 cases (4.1%) with true gene amplification. Among patients with
gene amplification, the median mean gene copy number was 10.28
(range, 4.87 to 27.50). MET FISH status was not associated with sex,
smoking status, or histology. In contrast, MET FISH-positive status
was significantly associated with grade 3 (P .016) and with advanced
stage (P .01). Among patients with MET gene amplification, three
had stage I disease, three had a stage II, nine had stage III, and three had
Table 1. Patient Characteristics
Characteristic Total %
Total 447
Median age, years 66
Range 33-86
Sex
Male 373 83.4
Female 74 16.6
Smoking history
Never 40 8.9
Former 232 51.9
Current 157 35.1
Unknown 18 4.1
Histology
Adenocarcinoma  bronchioloalveolar 241 53.9
Squamous cell carcinoma 139 31.1
Other 67 15.0
Pathologic stage
I 166 37.1
II 99 22.2
III 155 34.7
IV 27 6.0
Grade
I 32 7.2
II 255 57.3
III 158 35.2
Not defined 2 0.3
Other histology included seven patients with large cell carcinoma, 28 cases
with neuroendocrine differentiation, and 32 undifferentiated non–small-cell
lung cancer.
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Fig 1. (A) A total of 215 patients were
epidermal growth factor receptor (EGFR)
fluorescent in situ hybridization (FISH)
negative (57.2%), and 161 were EGFR
FISH positive (42.8%), including 122 with
EGFR high polysomy (32.4%) and 39 with
EGFR gene amplification (10.4%). Median
survival was 48.3 months for the low
polysomic group, 40.7 months for high
polysomic, and 30.7 months for patients
with gene amplification. (B) Patients with
high polysomy or gene amplification
(EGFR FISH) had a median survival of
40.7 months, while patients with low poly-
somy (EGFR FISH) had a median sur-
vival of 48.3 months. The difference was
not statistically significant (P  .4).
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stage IV. As shown in Figure 2B, in the whole populationMET FISH-
positive patients had a significant shorter survival than MET FISH-
negative (25.8 v 47.5 months;P .005). As illustrated in Figures 3A to
3D (Appendix and Appendix Figs A1 to A5, online only),MET FISH-
positive patients had shorter survival than MET-negative irrespective
of stage and grade, even if the difference was statistically significant
only in patients with stage I-II (P .032) and in individuals with
grade 3 disease (P .03).
MET Gene Copy Number and EGFR
To further explore the prognostic impact of MET gene copy
number in a context of EGFR gene gain or mutation, we analyzed
METaccording toEGFR status. Patients with adenocarcinoma with or
without bronchioloalveolar features and with stage I-II disease
(n  144) were screened for EGFR mutations, and 14 (9.7%)
harbored a deletion in exon 19 (seven patients) or the L858R
mutation in exon 21 (seven patients). No difference in survival was
observed between patients with or without mutation (67.1 v not
reached; P  .99). Interestingly, no patient with EGFR mutation
was MET FISH positive, and among EGFR wild type, MET FISH-
positive patients had significantly shorter survival thanMET FISH-
negative patients (P .005).
MET FISH-positive patients were more frequently EGFR FISH
positive, and that association was statistically significant (P .0001).
EGFR FISH negative/MET FISH negative had significantly longer
survival (55.9 v 22.6 months; P .0001) than EGFR FISH negative/
MET FISH positive (Fig 3E). Among patients EGFR FISH positive,
survival was longer inMETFISH-negative than inMETFISH positive
(42.6 v 28.9 months) even if the difference was not statistically signif-
icant (P .2; Fig 3F).
Table 2. Survival in EGFR FISH Positive and Negative Patients According to Clinical Characteristics
Characteristic EGFR FISH (No./month) EGFR FISH (No./month) P
Sex
Female 26/37.3 32/31.3 .9
Male 135/42.0 183/51.8 .4
Smoking status
Never smokers 13/40.7 17/NR .3
Smokers (former  current) 141/42.0 189/47.6 .7
Histology
Adenocarcinoma  bronchioloalveolar 87/40.7 111/44.6 .6
Other 74/39.6 104/50.2 .6
Grade
I-II 101/41.3 132/55.9 .11
III 60/37.3 81/36.6 .7
Stage
I-II 95/NR 129/NR .7
III-IV 66/20.5 86/25.6 .4
Abbreviations: EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; NR, not reached.
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Fig 2. (A) Survival outcome of patients
with a mean of  5 copies of MET/cell
was similar to the outcome of patients
with a mean of  6 copies of MET/cell,
and shorter than survival of patients with
less than 5 copies of MET/cell. Based on
these results, mean of  5 copies of
MET/cell qualified the result as MET.
Median survival was 22.3 months for the
10 patients with mean MET copy number
less than 2; 44.4 months in 129 individuals
with mean MET copy number  2 and
less than 3; 38.6 months for 149 patients
with mean MET copy number  3 and
less than 4; not reached for 95 patients
with mean MET copy number  4 and
less than 5; 28.1 months for 28 individuals
with MET copy number  5 and less than
6; 21.4 months for 20 patients with mean
copy number  6. (B) Patients MET fluo-
rescent in situ hybridization (FISH)
(n  48) had a median survival of 25.8
months versus 47.5 months in MET
FISH (n  383). This difference was
statistically significant (P  .0045).
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Univariable and Multivariable Analyses
Table 3 presents the results of the univariate and multivariate
survival analyses that included sex, stage, smoking history, grade,
histology,EGFRFISH, andMETFISH. In the univariate analysis, only
stage I-II (hazard ratio [HR], 0.40), and MET FISH-negative status
(HR, 0.59) were significantly associated with a reduced risk of death.
The multivariate model confirmed that patients with stage I or II and
patients MET FISH-negative had a lower risk of death than patients
with stage III or IV (HR, 0.42; P .0001) or MET FISH (HR, 0.66;
P .04). In order to explore the possible impact of EGFR mutations,
we further analyzed the risk of death according to the above men-
tioned categories in the 144 sequenced patients. In this model, that
excluded patients with stage III-IV disease with nonadenocarcinoma
histology, MET FISH-negative status was the only variable signifi-
cantly associated with a reduced risk of death (HR, 0.32; 95%CI, 0.14
to 0.71; P .006).
DISCUSSION
In this study we evaluated the prognostic role of two of the most
relevant biomarkers in NSCLC, and to our knowledge, report for the
first time thatMET increased gene copy number represents a negative
prognostic factor in radically resected NSCLC. MET FISH-positive
patients had a significantly shorter survival than MET FISH-negative
patients, and this negative prognostic effect was independent of any
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Fig 3. Survival of MET fluorescent in situ hybridization (FISH) and MET FISH according to stage, grade, and epidermal growth factor receptor (EGFR) FISH. (A) In
stage I-II disease, 20 patients were MET FISH and 233 were MET FISH. Median survival was not reached in MET FISH and was 33.0 months in MET FISH.
This difference was statistically significant (P .032). (B) In stage III-IV disease,MET FISH patients (n 28) had shorter survival (20.8 v 22.8 months) thanMET FISH
(n  150). This difference was not statistically significant (P  .3). (C) In grade 1-2 disease, MET FISH (n  23) had shorter survival (28.1 v 48.8 months) than MET
FISH (n  250). The difference did not reach the statistical significance (P  .1). (D) In grade 3 disease, MET FISH (n  25) had significantly shorter survival
(20.8 v 38.1 months) than MET FISH (n  131). The difference was statistically significant (P  .03). (E) EGFR FISH negative/MET FISH (n  197) had significantly
longer survival (55.9 v 22.6 months; P  .0001) than EGFR FISH/MET FISH (n  15). (F) Among patients EGFR FISH, survival was longer in MET FISH (n  128)
than in the 31 patients MET FISH (median survival, 42.6 v 28.9 months) even if the difference was not statistically significant (P  .2).
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other clinical or biologic characteristic, including those factors classi-
cally associated with sensitivity to EGFR-TKIs.4-6
MET has gained considerable interest through its apparent de-
regulation by overexpression or mutation in various cancers, includ-
ing NSCLC.41 Several anti-MET drugs are under evaluation in clinical
trials, and the interest around these compounds has consistently in-
creased since an interaction between EGFR and MET has been
observed.42 In addition, two recent studies showed thatMET amplifi-
cation is responsible for EGFR-TKI acquired resistance in approxi-
mately 20% of patients.33,36 Although the great interest onMET, only
few small studies evaluated whether this target could influence patient
survival.25,27,43-47 In the study conducted by Cheng et al43 in 45
NSCLC patients, overexpression of circulating c-MET was signifi-
cantly associated with early recurrence. In another study conducted in
106 NSCLC, Beau-Faller et al44 showed that adenocarcinoma patients
with MET amplification had a trend for poor prognosis. Our study,
conducted in a large series of non–small-cell lung cancer, provides
clear evidence that MET is a negative prognostic factor, further sup-
porting anti-MET strategies in this disease. Nevertheless, we cannot
rule out the hypothesis that the poor prognosis detected by the MET
FISH assay is not due to a broad level of genomic instability, since the
assay only investigated changes in chromosome 7. A relevant aspect of
our study was the significant association with EGFR gene copy num-
ber, similarly to what has been recently described by our group in
colorectal cancer.48 We found that approximately 20% ofEGFRFISH-
positive patients were also MET positive, raising the possibility that
someEGFRFISH-positive individuals could be resistant to EGFR-TKI
due to MET over-representation. Nevertheless, recent findings sug-
gested that only high levels ofMET amplification could impair EGFR-
TKI sensitivity.34 In this study, among EGFR FISH-positive patients,
only three patients had MET amplification at equal or higher than
levels previously reported in EGFR-TKI resistant models.33,36 More-
over, the lack of association between MET FISH-positive and EGFR
mutations and the rarity of coamplification of MET and EGFR genes
(only 1.1% in our cohort) suggest that chromosome 7 polysomy was
responsible for the significant association of MET FISH and EGFR
FISH status. The low incidence ofMET gene amplification observed
in our study is consistent with previous FISH studies showing that
MET amplification is a rare event in NSCLC, occurring in 3% to
7% of patients.33-35
Another interesting finding was the association of MET gene
copy number with tumor stage and grade. This aspect raises the
possibility that testing MET genomic status in tumor biopsies col-
lected at the time of primary diagnosis could not be reliable to predict
MET gene status in a tumor progressing after an initial treatment.
The second biomarker evaluated in this study was EGFR. Re-
cently, a large meta-analysis showed that EGFR expression was not a
prognostic factor in NSCLC.13 Three studies evaluated the prognostic
impact of EGFR gene copy number determined by FISH, and all
showed no association with patient survival.22-24 Results from large
phase III trials comparing an EGFR-TKI versus placebo, the only trials
able to discriminate between prognostic versus predictive value of a
biomarker, clearly showed that EGFR gene copy number represents a
predictive factor.8-9 Nevertheless, large phase III trials comparing
EGFR-TKI plus chemotherapy versus chemotherapy alone, also sug-
gested that EGFR increased gene copy number could contribute to a
better prognosis.11-12 Because of the confusion among clinicians on
the role of EGFR gene gain, and because in previous study we evalu-
ated the prognostic impact of EGFR FISH using a different scoring
system,22 in this study we analyzedEGFR gene copy number using the
same criteria described for selection of patients candidate for EGFR-
TKI therapy.5 Our results, obtained in a large patient population,
demonstrated that EGFR gene copy number has a limited effect on
patient survival. Although EGFR amplified patients had a trend for
shorter survival, the difference with nonEGFR-amplified individuals
was not significant and the whole group of EGFR FISH-positive pa-
tients had similar survival than EGFR FISH-negative patients, con-
firming that EGFR gene gain is not a favorable prognostic factor.
In conclusion, this study shows that MET increased gene copy
number is an independent prognostic factor in surgically resected
NSCLC, supporting anti-MET therapeutic strategies in selected pa-
tients. EGFR gene gain has no prognostic role in NSCLC, further
supporting its role as predictive factor for improved survival in
NSCLC patients exposed to EGFR-TKIs.
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